Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer’s Disease and Melatonin

@article{Spinedi2018NeuroendocrineMetabolicDA,
  title={Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer’s Disease and Melatonin},
  author={Eduardo Spinedi and Daniel P. Cardinali},
  journal={Neuroendocrinology},
  year={2018},
  volume={108},
  pages={354 - 364}
}
Alzheimer’s disease (AD) is associated with altered eating behavior and metabolic disruption. Amyloid plaques and neurofilament tangles are observed in many hypothalamic nuclei from AD brains. Some of these areas (suprachiasmatic nuclei, lateral hypothalamic area) also play a role in the regulation of the sleep/wake cycle and may explain the comorbidity of eating and sleep disorders observed in AD patients. Inadequate sleep increases the neurodegenerative process, for example, the decrease of… 

Figures from this paper

Melatonin levels in the Alzheimer’s disease continuum: a systematic review
TLDR
A systematic review showed that disruptions in melatonin levels occur with age, but also in AD when compared to age-matched controls, and the use of melatonin as potential blood biomarker for disease progression should also be further investigated.
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease
TLDR
The therapeutic potentials of melatonin are highlighted in preventing the acceleration of AD in T2DM individuals through its therapeutic mechanisms, including antioxidative effects, anti-inflammatory effects, restoring mitochondrial function and insulin sensitivity.
International Expert Opinions and Recommendations on the Use of Melatonin in the Treatment of Insomnia and Circadian Sleep Disturbances in Adult Neuropsychiatric Disorders
TLDR
The administration of prolonged release melatonin at 2–10 mg, 1–2 h before bedtime, might be used in the treatment of insomnia symptoms or comorbid insomnia in mood disorders, schizophrenia, in adults with autism spectrum disorders, neurocognitive disorders and during sedative-hypnotics discontinuation.
Melatonin Rescues the Dendrite Collapse Induced by the Pro-Oxidant Toxin Okadaic Acid in Organotypic Cultures of Rat Hilar Hippocampus
TLDR
Melatonin increased DNA fragmentation and reduced the number of MAP2(+) cells, whereas melatonin protected against oxidation and apoptosis and OKA decreased the dendritic arbor complexity, highlighting its role in post-synaptic domain integrity preservation against neurodegenerative events in hippocampal neurons.
Glymphatic System: Emerging Therapeutic Target for Neurological Diseases
TLDR
The present review will shed light on the structure, regulation, functions, and interrelationships of the glymphatic system and meningeal lymphatics, and their impairments and corresponding targeted intervention in neurodegenerative diseases, traumatic brain injury, stroke, and infectious/autoimmune diseases.
Cell Senescence and Central Regulators of Immune Response
TLDR
A multilevel system of central regulators involving neurotransmitters, glucocorticoids, melatonin, and the thymic hormones finely regulates the cell cycle and metabolic/catabolic processes depending on the level of systemic stress, stage of stress response, and energy capabilities of the body.
Melatonin in Wine and Beer: Beneficial Effects
TLDR
The bioavailability of melatonin and resulting metabolites, the presence ofmelatonin in wine and beer and factors that influence it, and finally the different benefits related to treatment with melatonin are evaluated.
Melatonin binds with high affinity and specificity to beta‐amyloid: LC‐MS provides insight into Alzheimer’s disease treatment
TLDR
Melatonin showed a high and specific binding for Abeta, and the results may suggest the potential mechanism of action of MT on Abeta and provide a theoretical basis for the improvement of MT treatment of Alzheimer's disease.
...
...

References

SHOWING 1-10 OF 116 REFERENCES
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
TLDR
It is found that brain interstitial fluid levels of Aβ were significantly correlated with wakefulness and negatively correlated with sleep, and chronic sleep restriction significantly increased, and a dual orexin receptor antagonist decreased, Aβ plaque formation in amyloid precursor protein transgenic mice.
Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.
TLDR
It is concluded that a dysfunction of noradrenergic regulation and the depletion of serotonin by increased monoamine oxidase A result in the loss of melatonin rhythm already in preclinical AD.
Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
TLDR
The neuroprotective functions of melatonin are discussed and evaluated, including its role in the classical hypotheses in cellular and animal models and clinical interventions in AD patients, and it is suggested that with early detection, melatonin treatment is qualified to be an anti-AD therapy.
Sleep and Alzheimer's disease.
Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease.
TLDR
Melatonin can be useful for treatment of Alzheimer's disease, and a significant improvement of sleep quality was found in all cases examined.
Slow wave sleep disruption increases cerebrospinal fluid amyloid-&bgr; levels
TLDR
Slow wave activity disruption increases amyloid-β levels acutely, and poorer sleep quality over several days increases tau, which suggests they are likely driven by changes in neuronal activity during disrupted sleep.
Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice
TLDR
Findings demonstrate that prophylactic MEL significantly reduces AD neuropathology and associated cognitive deficits in a manner that is independent of antioxidant pathways.
Transgenic Mice Overexpressing Amyloid Precursor Protein Exhibit Early Metabolic Deficits and a Pathologically Low Leptin State Associated with Hypothalamic Dysfunction in Arcuate Neuropeptide Y Neurons
TLDR
The results indicate that excess Aβ can potentially disrupt hypothalamic arcuate NPY neurons leading to weight loss and a pathologically low leptin state early in the disease process that progressively worsens as the amyloid burden increases.
...
...